Engflag

Eravacycline

Quick links to important sections

Eravacycline

Eravacycline_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eravacycline

Quick Facts

Property Description
Active ingredient Eravacycline
Form Lyophilized powder for injection
Pharmacological class Antibiotic (Fluorocycline/Tetracycline Class)
Common use Treating serious bacterial infections
Origin Synthetic derivative

What Type of Medicine is Eravacycline?

Eravacycline is a modern, synthetic antibacterial agent used to manage certain serious infections. It belongs to the fluorocycline group, which is a specialized derivative of the older tetracycline antibiotic class. The drug is a single-ingredient product whose development focused on overcoming bacterial resistance mechanisms that render many traditional antibiotics ineffective. The design is intended to enhance its capacity to overcome established resistance mechanisms, making it a treatment option in clinical scenarios where antibiotic resistance is a significant concern.

Eravacycline is classified as an antibiotic/antibacterial agent because its primary role is to inhibit the growth and proliferation of harmful bacteria. It works by targeting and binding to the bacterial ribosomal 30S subunit, a key structure required for the production of essential proteins. This action stops the bacteria from being able to grow and multiply, achieving a bacteriostatic effect. Eravacycline is designed for difficult-to-treat infections due to its ability to circumvent common resistance patterns, such as efflux pump mechanisms.

Eravacycline Dosage Form and Composition

Eravacycline is supplied exclusively as a lyophilized powder for injection within a single-dose vial, making it an injectable formulation. This solid powder contains the active ingredient, Eravacycline, which must be reconstituted with an appropriate liquid diluent before its administration.

It is strictly administered via intravenous infusion, meaning it is given directly into a vein. This exclusive parenteral administration route is used for patients requiring rapid and consistently high levels of the active ingredient to manage serious infections in a hospital setting.

What side effects are possible with Eravacycline?

Possible Side Effects and Safety Information

The safety profile of eravacycline is structured around expected administration site reactions, common gastrointestinal disturbances, and specific risks associated with its classification as a tetracycline-class antibiotic. Officially documented adverse reactions are categorized by frequency and system involvement.

Frequency-Classified Adverse Reactions

Adverse reactions listed in regulatory documents are often categorized by the frequency observed in clinical data:

  • Common (may affect up to 1 in 10 people): Reactions at the infusion site (such as pain or phlebitis), nausea, vomiting, and diarrhea are frequently reported. Hypotension and wound dehiscence are also listed in this category.
  • Uncommon (may affect up to 1 in 100 people): Includes elevations in liver enzymes (increased ALT and AST), hyperbilirubinaemia, headache, and certain hypersensitivity reactions.

Serious Adverse Reactions and Key Constraints

Regulatory safety information highlights several serious or clinically significant risks that are either associated with eravacycline or shared across the tetracycline antibiotic class:

  • Tetracycline Class Effects: Use during specific periods of tooth and bone development (the last half of pregnancy, infancy, and childhood up to age 8) may lead to permanent tooth discoloration and reversible inhibition of bone growth. Use is generally avoided in these populations.
  • Clostridioides difficile-associated diarrhea (CDAD) is a serious gastrointestinal condition documented with nearly all antibacterial agents.
  • Hypersensitivity reactions and pancreatitis are also officially noted as potential serious adverse reactions.

Safety constraints prohibit the use of eravacycline in individuals with a known allergy to the medicine or to other tetracycline-class antibiotics.

Overdose and Emergency Response

Eravacycline Overdose and When to Seek Help

The official prescribing information for eravacycline (XERAVA) outlines management strategies for an overdose, primarily based on supportive care rather than specific symptoms, as no unique overdose manifestations are documented.

Required Emergency Actions

In the event of a suspected overdose, the drug should be discontinued immediately. Management consists of providing supportive treatment while monitoring the patient for adverse reactions. There is no specific antidote for eravacycline, and the extent to which it may be removed by hemodialysis is unknown.

Serious Risks and When to Seek Urgent Medical Attention

Urgent medical attention is necessary if signs of a serious reaction, such as a life-threatening hypersensitivity (anaphylactic) reaction, occur during treatment or after an overdose. In such cases, the medication must be stopped, and appropriate emergency measures must be initiated immediately.

Additionally, as a member of the tetracycline class of antibacterial drugs, the potential for serious class-related adverse effects must be monitored. These may include signs of anti-anabolic effects (e.g., increased blood urea nitrogen, acidosis) or liver function abnormalities (e.g., pancreatitis), which require close medical observation following excessive exposure.

Therapeutic Uses of Eravacycline

Eravacycline is an antibiotic that is used in clinical settings to address bacterial infections. It is indicated for the management of complicated intra-abdominal infections (cIAI) in adults. This medication is applied in therapeutic domains involving conditions characterized by periods of heightened symptoms, where supportive symptomatic assistance is needed.

Managing Discomfort During Acute Episodes

Eravacycline is used in clinical scenarios when an acute infection causes symptoms to intensify and become more noticeable, where symptoms may create functional strain and demand supportive management. The intended benefit is providing support that helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods.

Quick Fact: Relief for Systemic Discomfort

How It Helps

The medication supports patients during difficult episodes by helping to manage symptoms that are linked to organ-specific functional stress. Eravacycline is used for the management of conditions that present with disruptive symptom manifestations.

Regulatory References

  1. European Medicines Agency overview on Xerava

Eligibility and Restrictions for Use

Who can and cannot use Eravacycline?

Eravacycline's eligibility is strictly defined by regulatory documents based on patient population and pre-existing conditions.

Eligibility Scope

Population Status Eligibility Classification
Contraindications Prohibited for patients with known hypersensitivity to eravacycline, other tetracycline-class antibacterial drugs, or any excipients.
Adults (≥18 yrs) Allowed under standard labeled conditions, including older adults (≥65 years).
Children < 8 yrs Not Recommended due to the risk of permanent tooth discoloration and bone growth inhibition.
Pregnancy/Lactation Not Recommended during the last half of pregnancy or while breastfeeding (and for 4 days post-treatment).
Renal Impairment Allowed for all degrees of renal impairment without dosage adjustment.
Severe Hepatic Impairment Restricted Use: Permitted only with a mandatory modified dosage regimen starting on Day 2 of treatment.

Resulting Eligibility Structure

Official regulatory documents define absolute contraindications based on hypersensitivity reactions to the drug or the tetracycline class. Use is explicitly not recommended for populations undergoing developmental stages (children under 8, late-stage pregnancy) due to the documented risk of permanent dental defects. Eligibility for the adult population is affirmed, with conditional use required only for those with severe liver impairment (Child-Pugh C) or those receiving specific strong enzyme inducers.

What should I know about interactions with other medicines?

Eravacycline’s interaction profile is characterized primarily by its metabolism via the CYP3A4 enzyme system. This leads to a necessary dose modification when co-administered with strong CYP3A inducers.

Interactions Requiring Dose Adjustment

Interacting Product Category Effect on Eravacycline Management (Dose Adjustment)
Strong CYP3A Inducers (e.g., rifampin, carbamazepine, St. John’s Wort, phenytoin) Significantly decreases Eravacycline exposure, potentially reducing effectiveness. The Eravacycline dose must be increased to 1.5 mg/kg every 12 hours for the duration of the co-administration.

Other Significant Interactions

  • Anticoagulant Drugs: As a drug of the tetracycline class, Eravacycline may depress prothrombin activity, which is a measure of blood clotting. Patients taking oral anticoagulants (e.g., warfarin) may require a downward adjustment of the anticoagulant dosage, and close monitoring of coagulation parameters is recommended.
  • Strong CYP3A Inhibitors: The co-administration of strong inhibitors (e.g., itraconazole) slightly increases Eravacycline exposure; however, no dose adjustment is typically required in healthy individuals. Monitoring for adverse reactions is recommended for patients with co-existing risk factors such as severe hepatic impairment or obesity.
  • Tetracycline-Class Hypersensitivity: Eravacycline is structurally related to other tetracycline-class antibacterial drugs. Its use is contraindicated in patients with known hypersensitivity to any drug in this class.

Mechanism of Action

Targeting the Core Machinery for Bacterial Protein Synthesis

Eravacycline works by exerting a targeted inhibitory action on the bacteria’s 30S ribosomal subunit . This high-affinity molecular interaction blocks the site where amino acids are incorporated into new proteins, resulting in the immediate arrest of peptide chain elongation and the subsequent cessation of bacterial growth (a bacteriostatic effect).

Overcoming Acquired Antibiotic Resistance

The mechanism also involves the ability to circumvent two major resistance pathways: bacterial efflux pumps and ribosomal protection proteins. By maintaining its physical bond to the 30S subunit despite these defenses, Eravacycline is able to achieve a sustained inhibitory effect, which is the mechanism's primary contribution to its functional effect against resistant pathogens.

The Physiological Consequence: Stasis and Viability Loss

The rapid, sustained shutdown of protein production shifts the bacteria from an active growth state to stasis (no proliferation). This profound physiological change controls the population of viable bacteria, and in susceptible strains, the intensity of the protein blockade leads directly to loss of cell viability (a bactericidal effect).

Dosage and Administration Information

How Eravacycline is Used

Eravacycline is administered exclusively via intravenous (IV) infusion in a controlled clinical setting. It is supplied as a lyophilized powder in single-dose vials (50 mg or 100 mg) that require specific preparation prior to administration. The powder must first be reconstituted and then further diluted into an IV bag; the preparation process involves swirling the vial gently, not shaking, to prevent foaming. The treatment is administered over a duration of approximately 60 minutes per dose.

The typical duration of treatment is 4 to 14 days, guided by the treating physician based on the specific condition and the patient's clinical response.

Dosing and Administration Schedule

The standard regimen for adults is a weight-based dose of 1 mg/kg of actual body weight, administered every 12 hours (twice daily). When co-administered with a strong Cytochrome P450 (CYP) 3A inducer, the dose is increased to 1.5 mg/kg.

Special Use Condition Dosage Instruction
Severe Hepatic Impairment The dose is reduced to 1 mg/kg every 24 hours starting on Day 2, following the standard dose on Day 1.
Renal Impairment No dose adjustment is required for any degree of renal impairment.
Pediatric Use Efficacy and safety have not been established; use is generally advised against in children under 8 years of age.

The administration and preparation procedures emphasize the exclusive parenteral route and standardized twice-daily schedule for its entire course of use.

Recent Clinical Evidence

Research evidence / Overview of studies for Eravacycline

Evidence for use in Complicated Intra-Abdominal Infections (cIAI)

The primary research base for Eravacycline stems from studies evaluating complicated intra-abdominal infections (cIAI) in adults. The core evidence consists of two large-scale, international Phase 3 randomized controlled trials (RCTs) known as IGNITE 1 and IGNITE 4. These studies were designed to compare Eravacycline against active comparator antibiotics, such as ertapenem and meropenem.

The studies included hospitalized adult patients with cIAI who required an intervention, such as surgery or drainage. Researchers explored the evaluation of the drug in patients with polymicrobial infections involving different types of bacteria. Retrospective observational studies also contribute to the evidence landscape.

The findings described measurements of Clinical Response in these populations, with results structured to address the research question of non-inferiority. Studies reported how symptoms evolved in the observed populations and tracked outcomes related to the microbiological response for the pathogens.

Outcomes Measured in Pivotal Clinical Trials

Pivotal trials were designed to measure a Clinical Cure Rate, which was defined as the complete resolution or significant improvement of signs and symptoms related to the infection. This primary outcome was assessed at a fixed point in time, known as the Test-of-Cure (TOC) visit. Studies monitored microbiological responses related to specific bacterial species. Research examined the Microbiological Response Rates for common cIAI pathogens, including those that may exhibit resistance to other antibiotics.

What is Still Unknown About Eravacycline Research

The research base primarily covers the single indication of cIAI. Long-term outcomes and the durability of the reported effects beyond the 30-day observation period are not fully established by the existing core trials. Research exploring outcomes in patient populations with the most severe illness, such as those with septic shock, remains limited, as these patients were generally excluded from the pivotal trials. The existing clinical data remains insufficient to establish use in children younger than 8 years of age.

Key Studies & References

  1. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial
  2. The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Eravacycline (FAQ)

Q: What is Eravacycline used for, in simple terms?

A: Eravacycline is a specialized prescription medicine, described in official documents as an antibacterial agent. It is used to treat specific, serious bacterial infections in adults, such as complicated intra-abdominal infections (cIAI). Its use is limited to clinical scenarios where an intravenous treatment is necessary for a targeted infection.

Q: Is Eravacycline considered a strong antibiotic?

A: Official documents describe Eravacycline as a fluorocycline antibiotic that works by overcoming certain bacterial defense mechanisms, such as efflux pumps. This design makes it a therapeutic option for difficult-to-treat infections where common resistance patterns are a concern. The importance of completing any prescribed course of antibacterial treatment is generally recognized.

Q: Has anyone experienced severe side effects from Eravacycline?

A: The official product information documents the potential for serious adverse reactions. These include reports of pancreatitis and a severe form of diarrhea called Clostridioides difficile-associated diarrhea (CDAD). These risks are not unique to Eravacycline and are associated with nearly all antibacterial agents.

Q: Is it okay to take multivitamins while on Eravacycline?

A: Due to the drug’s class, official documents indicate that Eravacycline may interact with products containing polyvalent cations, such as aluminum, calcium, iron, or magnesium. Since multivitamins often contain these substances, official sources suggest that patients receiving the antibiotic may need to discuss the timing of administration relative to these products.

Q: How is Eravacycline different from other antibiotics I've taken?

A: Official regulatory documents state that Eravacycline belongs to the fluorocycline group, a derivative of the tetracycline class. Its structure was specifically engineered to circumvent key defense mechanisms used by resistant bacteria, such as efflux pumps. This mechanism allows it to maintain its activity against certain resistant pathogens.

Q: Are there any long-term effects of using Eravacycline?

A: Studies and official information indicate that the core pivotal trials for Eravacycline primarily covered outcomes for an observation period of up to 30 days after treatment. As a result, data regarding long-term outcomes and the durability of effects beyond that period are limited.

Q: Do I need any special monitoring while receiving Eravacycline?

A: According to the official product information, patients may require routine monitoring of laboratory tests while receiving Eravacycline. Specific monitoring is recommended for patients taking oral anticoagulants (blood thinners), as their coagulation parameters (blood clotting measures) may need close attention.

Q: What is the chance of an allergic reaction to Eravacycline?

A: The official product information documents that hypersensitivity reactions are potential adverse reactions. Eravacycline is strictly prohibited (contraindicated) for anyone with a known allergy to the medicine or any other drug in the tetracycline class.

Q: Can Eravacycline treatment be stopped early?

A: Regulatory documents describe the standard treatment course as typically lasting between 4 and 14 days, with the duration guided by a healthcare provider. The standard approach is to complete the full prescribed course, as this is recognized as essential for the efficacy of antibacterial treatment.

Q: Is Eravacycline only for use in hospitals?

A: According to official documents, Eravacycline is supplied as a powder that must undergo specific preparation, reconstitution, and dilution. It is administered exclusively by intravenous infusion in a controlled clinical setting, which is typically a hospital or inpatient facility.

Q: Why do doctors prescribe Eravacycline instead of other options?

A: Regulatory documents indicate that Eravacycline is prescribed for specific, serious infections. Its design is particularly valued because its mechanism of action allows it to remain effective against certain bacteria that have developed ways to resist older antibiotics.

Q: Is Eravacycline approved in countries outside the US?

A: Yes, Eravacycline has received authorization for use in several major international jurisdictions outside the United States. These include the European Union (EMA), Canada (Health Canada), and Australia (TGA).

Q: How long does Eravacycline stay in your system?

A: Official product information describes the drug’s half-life, which is the time it takes for half of the medicine to be cleared from the plasma. For Eravacycline, the half-life is stated to be approximately 43 hours after a single intravenous dose.

Q: Can Eravacycline interact with common pain relievers?

A: Eravacycline is processed by the liver's CYP3A4 enzyme system. The regulatory prescribing information focuses on dose adjustments needed when it is used with strong CYP3A inducers. It does not specifically name all common pain relievers, and questions regarding potential interactions are typically best addressed by a healthcare provider.

Q: Are there any major food or drink restrictions with Eravacycline?

A: According to the official product information, Eravacycline is given by intravenous infusion directly into a vein. Therefore, no dedicated food-effect study was conducted, as the drug is not impacted by food or fluid intake in the digestive system.

Q: Is Eravacycline used for skin infections?

A: Regulatory documents state that Eravacycline is officially indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. It is not currently indicated for other types of infections, such as skin infections.

Q: Is Eravacycline used for common urinary tract infections (UTIs)?

A: Eravacycline is officially indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. It is not indicated for use against common urinary tract infections (UTIs).

Q: What if I feel dizzy or lightheaded after receiving Eravacycline?

A: Official documentation lists hypotension (a drop in blood pressure) as a common adverse reaction. Since hypotension can sometimes cause a feeling of lightheadedness or dizziness, unexpected changes, such as dizziness or lightheadedness, are points of information that are important for the prescribing healthcare provider to know.

Q: Does Eravacycline make you sensitive to sunlight?

A: Yes, the official labeling includes a warning, common to the tetracycline class of antibiotics, regarding a potential risk of photosensitivity. This means the skin may have an exaggerated sunburn-like reaction to exposure to sunlight or UV light.

Q: Is Eravacycline similar to Tigecycline?

A: Official documents state that Eravacycline is a modern, synthetic antibiotic that belongs to the fluorocycline group. This makes it structurally related to the wider tetracycline class of antibiotics, which includes other agents like Tigecycline.

Q: Does Eravacycline have a Black Box Warning?

A: According to the US Prescribing Information, Eravacycline does not include a Black Box Warning (officially known as a Boxed Warning). This warning is a regulatory mechanism used to call attention to specific serious risks associated with a medication.

Q: Is Eravacycline effective against MRSA?

A: Official documents regarding the drug’s activity confirm that Eravacycline has demonstrated activity against several key pathogens, including Methicillin-resistant Staphylococcus aureus (MRSA), in laboratory studies. This activity is part of its design to target resistant bacteria.

Q: Does Eravacycline interact with calcium supplements?

A: As a drug in the tetracycline class, the official labeling includes warnings regarding the potential for interactions with products containing polyvalent cations. These include substances like calcium, iron, or magnesium, which can interfere with the antibiotic's effectiveness.

How should Eravacycline be stored and disposed of?

How to Store and Dispose of Eravacycline

Eravacycline (Xerava) in its unopened vial must be stored in a refrigerator between 2 C to 8 C (36 F to 46 F) and kept within its original carton to protect it from light. It is essential that the drug is not frozen at any point.

Preparation Stage Temperature Constraint Time Constraint
Reconstituted in Vial Room Temperature (up to 25 C) leq 1 hour (must be diluted or discarded)
Diluted IV Solution Room Temperature (up to 25 C) leq 24 hours
Diluted IV Solution Refrigerated (2 C to 8 C) leq 10 days

During reconstitution and dilution, do not shake the vial or bag. Since eravacycline is supplied in a single-dose vial, any unused portion of the reconstituted or diluted solution must be immediately discarded after use. Disposal should adhere to local governmental requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Eravacycline found in:

A-Z Index: